Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
复制标题
聚合酶链反应检测慢性粒细胞白血病患者骨髓移植后的分子复发。
DOI:
10.1073/pnas.87.2.563
复制
发表时间:
1990
影响因子:
11.1
通讯作者:
Champlin,R
中科院分区:
文献类型:
--
作者:
Sawyers,CL;Timson,L;Kawasaki,ES;Clark,SS;Witte,ON;Champlin,R
Relapse of chronic myelogenous leukemia after bone marrow transplantation can be detected by using clinical, cytogenetic, or molecular tools. A modification of the polymerase chain reaction can be used in patients to detect low levels of the BCR-ABL-encoded mRNA transcript, a specific marker for chronic myelogenous leukemia. Early detection of relapse after bone marrow transplantation could potentially alter treatment decisions. We prospectively evaluated 19 patients for evidence of molecular relapse, cytogenetic relapse, and clinical relapse after bone marrow transplantation. We used the polymerase chain reaction to detect residual BCR-ABL mRNA in patients followed up to 45 months after treatment (median, 15 months; range, 6-45 months) and found 4 patients with BCR-ABL mRNA expression following bone marrow transplantation. In 2 patients BCR-ABL mRNA was detected in all samples, and both have developed cytogenetic relapse. In 1 patient BCR-ABL mRNA was detected transiently during the first month after transplant but was undetectable thereafter. The fourth patient had BCR-ABL mRNA 6 months after bone marrow transplantation but not in prior samples. Fifteen patients did not express detectable BCR-ABL mRNA. All 19 patients remain in clinical remission. In this prospective study of chronic myelogenous leukemia patients treated with bone marrow transplantation, molecular relapse preceded cytogenetic relapse in those patients who persistently express BCR-ABL mRNA. We recommend using standard clinical and cytogenetic testing to make patient care decisions until further follow-up determines the clinical outcome of those patients with residual BCR-ABL mRNA transcripts detected by polymerase chain reaction.
登录
查看更多内容
影响因子:
20.3
作者:
M. Berthéas;D. Maraninchi;M. Lafage;J. Fraisse;D. Blaise;A. Stoppa;G. Michel;C. Brizard;M. Gaspard;G. Novakovitch
通讯作者:
G. Novakovitch
DOI:
10.1073/pnas.82.6.1810
发表时间:
1985-01-01
影响因子:
11.1
作者:
KONOPKA, JB;WATANABE, SM;WITTE, ON
通讯作者:
WITTE, ON
DOI:
10.1093/jnci/25.1.85
发表时间:
1960-07
期刊:
Journal of the National Cancer Institute
影响因子:
--
作者:
P. Nowell;D. Hungerford
通讯作者:
P. Nowell;D. Hungerford
影响因子:
20.3
作者:
Ming;A. Lemaistre;H. Kantarjian;Moshe Talpaz;Emil J. Freireich;Jose M. Trujillo;Sanford A. Stass
通讯作者:
Sanford A. Stass
影响因子:
20.3
作者:
Alexander Dobrovic;Kevin J. Trainor;Alexander A. Morley
通讯作者:
Alexander A. Morley